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Introduction: Local anesthetics (LAs) are frequently used during anesthesia; however, they 
may influence granulocyte function which in turn could modify immune responses in the 
perioperative period. Therefore, the aim of this study was to investigate the impact of 
clinically used doses of bupivacaine and lidocaine on granulocyte function with regard to 
migration, reactive oxygen species (ROS) production, neutrophil extracellular traps 
(NETosis) formation, and viability.
Methods: A total of 38 granulocyte-enriched samples from healthy subjects were obtained 
by whole blood lysis. Polymorphonuclear neutrophil (PMN) samples were incubated simul-
taneously with different concentrations of either bupivacaine (0.03–3.16 mmol/L) or lido-
caine (0.007–14.21 mmol/L), or without drug (control). Live cell imaging was conducted in 
order to observe granulocyte chemotaxis, migration, ROS production, and NETosis. Flow 
cytometry was used to analyze viability and antigen expression.
Results: The track length (TL) of PMNs exposed to bupivacaine concentrations of 0.16 
mmol/L and above significantly decreased compared to the control. Low concentrations of 
lidocaine were associated with slight but significant increases in TL, whereas this changed 
with concentrations above 1.4 mmol/L, showing a significant decrease in TL. PMN incu-
bated with bupivacaine concentrations of 1.58 mmol/L and above or lidocaine concentrations 
of at least 3.6 mmol/L showed no migration or chemotaxis at all. Time to onset of maximal 
ROS production and time for half-maximal NETosis decreased in a dose-dependent manner 
for both substances. Equipotency in NETosis induction was reached by bupivacaine (1.1 
mmol/L) at significantly lower concentrations than lidocaine (7.96 mmol/L). Cell viability 
and oxidative burst were unaffected by LAs.
Conclusion: Local anesthetics in clinically used doses ameliorate granulocyte defense 
mechanisms, thus indicating their potentially decisive effect during the perioperative period.
Keywords: local anesthetics, granulocytes, immune modulation, surgical trauma, 
inflammation
Introduction
Ever since the discovery of cocaine’s local anesthetic properties in the mid-19th 
century, local anesthetics (LAs) have been used in surgery and modern anesthesio-
logic interventions (eg, epidural or spinal anesthesia, local nerve and wound 
infiltration) would not be possible without them.1–3 In recent years, several studies 
have shown significant immunomodulation with LAs caused by interactions with 
polymorphonuclear granulocytes (PMNs). Although PMNs are considered to be 
electrically non-excitable, the predominant mechanisms4–8 for the modulations are 
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thought to be the inactivation of voltage-gated sodium 
channel 1.3 (NaV 1.3), non-canonical effects such as the 
blocking of inflammatory mediators, antiapoptotic effects 
or reduced vascular adhesion, and trans-endothelial migra-
tion capacity. The amide type LAs bupivacaine and lido-
caine are on the WHO’s list of essential drugs9,10 and may 
also have antitumor effects for several tumor entities.11,12 
Furthermore, a recent study by Tohme et al observed that 
neutrophil extracellular traps (NETs), which are chromatin 
DNA released by PMNs, were implicated in colorectal 
carcinoma liver metastasis after surgical stress.13 Galos 
et al could observe reduced NETosis in women treated 
with intravenous lidocaine during breast cancer surgery 
which might result in lower recurrence rates.14
The perioperative period is a decisive time in which it 
turns out if the patient has benefitted from the surgery. 
Depending on the country, mortality rates due to surgical 
traumata are up to 4%, severe morbidity rates range 
between 5% and 15%, and around 15% of patients have 
to be readmitted to hospital within 30 days. It has been 
estimated that up to 50% of these problems could be 
avoided.15,16 After surgical trauma, the anti-inflammatory 
response is designed to maximize host defense. As 
a consequence, an anti-inflammatory state with reduced 
immunocompetence follows the host initially having 
a highly activated immune system.16,17 Therefore, perio-
perative immunomodulation could result in deleterious 
effects when this fragile equilibrium is disturbed.
As PMNs represent the majority of circulating inflam-
matory cells and are the first line of host defense, they 
inherently play a pivotal role in this perioperative period. 
As such, we investigated the impact of clinically used 
doses of amide type LAs bupivacaine and lidocaine on 
the function of isolated granulocytes by performing 
in vitro assays for the comparative and time-resolved 
analysis of granulocyte chemotactic migration capacity, 
reactive oxygen species (ROS) production, neutrophil 
extracellular trap formation (NETosis), time-dependent 




After approval by the local ethics committee of the 
University of Regensburg (Vote No: 12–101-0192) and 
informed consent was obtained, 7.5 mL of whole blood 
was drawn from 17 healthy blood donors (Table 1) and 
anti-coagulated in test-tubes with lithium heparin. The 
samples were purified by short-term hypotonic lysis for 
30 seconds at ambient temperature (21°C) using a purified 
aq. dest. and sodium chloride solution for reconstitution 
(Merck, Darmstadt, Germany). The lysed blood samples 
were centrifuged for 5 minutes at 425 g, obtaining 
a leucocyte-enriched cellular sediment. Each sample was 
split into aliquots for treatment (variables: concentrations 
of local anesthetics) and detection (methods: live cell 
imaging and flow cytometry).
Microscopy and Live Cell Imaging
This experimental setup was based on previous 
experiments.18–20 In brief, the cells were examined in tem-
poral resolution by light and fluorescence microscopy over 8 
hours. 3D-µ-slides (ibidi© GmbH, Martinsried, Germany) 
were used to perform a chemotactic assay. Each µ-slide 
consisted of three separate channels with each channel bor-
dered by two reservoirs. Following the manufacturer’s 
instructions, the cells were embedded in collagen gel 
(1.5 mg/mL PureCol, Advanced BioMatrix, Carlsbad, 
USA) and followed by fluorescent stains. This cell-enriched 
gel matrix was filled into the µ-slide channels and incubated 
under humid conditions for 30 minutes at 37°C and 5% CO2. 
Immediately before microscopy, a chemoattractant (CA) 
N-formyl-met-leu-phe (fMLP, Sigma Aldrich, St. Louis, 
USA) was introduced to the reservoir on the left of each 
channel, instantly creating a linear gradient provoking che-
motactic PMN movement. Along with the CA, medium 
RPMI 1640 (PAN-Biotech GmbH, Aidenbach, Germany) 
with 10% fetal calf serum (FCS, Sigma Aldrich, Steinheim, 
Germany) and the chosen local anesthetic concentration of 
either bupivacaine hydrochloride monohydrate or lidocaine 
hydrochloride monohydrate (both Sigma Aldrich, Steinheim, 
Germany) were applied. The intracellular ROS production 
was visualized using 1 µM dihydrorhodamine-123 (DHR- 
123, Molecular Probes Inc., Eugene, USA) by detecting its 
Table 1 Characteristics of the Study Population
Characteristics Value
Number of subjects 17
Gender (female/male) 8/9
Age [years] 27 [22–63]
Height [cm] 172 [161–191]
Weight [kg] 76 [37–91]
BMI [kg/m2] 26 [21–29]
Note: Mean values and [range].
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fluorescent product rhodamine-123. Utilizing the NETosis- 
associated release of extracellular DNA, NET formation was 
visualized with 0.5 µg/mL 4‘,6-diamidin-2-phenylindol 
(DAPI, Sigma Aldrich, Steinheim, Germany).
Live cell imaging was done using a Leica DMi8 micro-
scope in combination with a motorized adjustable microscope 
stage, a Leica DFC9000 camera and a pE-4000 light source 
(CoolLED, NY, USA). Leica Application Suite X software 
(version 3.4.2.18368, all Leica equipment from Leica 
Microsystems, Wetzlar, Germany) automatically recorded 
phase contrast images and both fluorescence images (in total 
9 frames per cycle). The turn-around time was 35±2 seconds 
over a time span of 8 hours. In every assay, stable test condi-
tions were maintained using a stage top incubator (ibidi).
Image Data Analysis
Image sequences obtained consisting of 2700 frames per µ- 
slide were analyzed using Imaris software (versions 9.0.2 
and 9.0.3, bitplane, Zurich, Switzerland). Phase contrast 
images provided the basis for migratory analyses. Cell 
migration was analyzed in 30-minute periods and was 
detected up to 3 hours after cell-gel contact. Cell-gel contact 
occurred approximately 45 minutes before exposure to local 
anesthetics and 50 minutes before the beginning of micro-
scopic evaluation. Imaris recognized the cells that match the 
selected criteria, determined spots and calculated tracks for 
every moving cell. The received data included the following 
parameters: Track Displacement (TD, Euclidean track; in 
total as well as subdivided into x- and y-directed move-
ment), Track Straightness (Str, fraction of Euclidean track 
length and total track length epitomizing the cell’s directness 
with a maximum of 1 for linear movement), Mean Track 
Speed (v), and Track Length (TL, accumulated Track). To 
exclude passive cells and reduce artefacts due to spots on 
non-PMN, tracks under 25 µm Track Length and under 
a duration of 800 s were excluded.
ROS production and NETosis were quantified by detect-
ing the fluorescent area and processing the total surface areas 
per time point (Figure 1). Both of these PMN functions 
visualized in Excel (Microsoft Excel 2016) showed charac-
teristic graphs, with a parabolic curve for ROS-production 
and a sigmoidal curve for NETosis. To analyze ROS produc-
tion, the time of maximal intracellular ROS was calculated 
by creating and fitting a third degree polynomial trendline to 
the graph and extracting the matching equation.
To calculate ET50NET, the data were processed using 
Phoenix 64 version 8.0.0 (Certara, New York, USA).
Flow Cytometry
In addition to live cell imaging, an aliquot of the cells was 
observed using flow cytometry (FACSCalibur) in combi-
nation with CellQuest Pro software version 5.2 (both from 
BD Biosciences, San Jose, USA). All analyses were per-
formed using FlowJo software version 10.0.7 (FlowJo 
LLC, Ashland, OR, USA). The methods used were: an 
oxidative burst to observe ROS production, and detection 
of cell-surface antigens CD11b, CD62L and CD66b.21,22
For the oxidative burst, cells were preincubated in 1 mL of 
Dulbecco’s phosphate-buffered saline (DPBS, Sigma Aldrich, 
Steinheim, Germany), 10 µL DHR 123 (10 µM), and 10 µL 
seminaphtharhodafluor (SNARF, 10 µM, Invitrogen, Eugene, 
USA). The oxidative burst was triggered by adding either 10 
Figure 1 ROS production (TmaxROS) and NETosis (ET50NET) visualized by time-related total surface areas.
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µL fMLP (10 µM) and 10 µL tumor necrosis factor alpha 
(TNFa, 1 µg/mL, Pepro Tech Inc., Rocky Hill, USA), or 10 
µL phorbol-12-myristate-13-acetate (PMA; 10 µM, Sigma- 
Aldrich). A concentration of local anesthetic identical to that 
of the live cell imaging samples was made up simultaneously. 
To assess cell vitality, 5 µL Propidium Iodide (PI, 1.5 mM, 
Invitrogen, Eugene, USA) was added.
Finally, for cell-surface antigen expression detection, 
the antibodies mentioned above and labelled either phy-
coerythrin (PE, CD11b ICRF44), fluorescein isothiocya-
nate (FITC, CD62L DREG-56), or allophycocyanin (APC, 
CD66b G10F5, all BioLegend) were used.
Statistical Analysis
Data from live cell imaging and flow cytometry were 
collected in Excel (Microsoft Excel 2016). SPSS 
Statistics version 25 (IBM Corp., Armonk, NY, USA) 
was used for further statistical analyses. Initially, normal 
distribution was tested with the Kolmogorov–Smirnov- 
test. Based on non-existing normal distribution, 
a Kruskal–Wallis one-way analysis of variance (ANOVA) 
was used to compare the groups. Bonferroni correction 
(method) was used in post hoc analysis and P-values 
below 0.05 were considered statistically significant. The 
distribution of results is visualized with boxplots display-
ing median, lower quartile, and calculated minima and 
maxima. Statistical outliers are represented as circles, 
and extreme values are depicted as asterisks.
Results
Migration
The median track count per concentration of bupivacaine 
with detectable migration was n=208 (range 95–309).
The median track count per concentration of lidocaine 
with detectable migration was n=376 (range 273–467).
Bupivacaine
With increasing concentrations of bupivacaine, the TL 
values decreased (Table 2). In the first 30 minutes the 
median TL of the control group was 278 µm, whereas 
cells under 0.03 mmol/L bupivacaine showed a significant 
(p=0.021) lower median TL of 226 µm (80.6% of control 
group). For 0.95 mmol/L bupivacaine, the median TL was 
49.9 µm (17.8% of control group). Migration was only 
detectable in concentrations up to 0.95 mmol/L. Higher 
concentrations resulted in immediate and absolute granulo-
cyte arrest at the beginning of observation (all migration 
parameters at zero) and were considered significantly differ-
ent to every other group below that concentration.
Over the following two time periods, this TL reduction 
equalized in the groups of 0.03, 0.09, and 0.58 mmol/L com-
pared to the control group (median TL 2nd period = 252 µm; 
3rd period = 167 µm). By contrast, the groups of 0.32, 0.63, 
and 0.95 mmol/L (median TL 2nd period = 41.1 µm; 3rd 
period = no migration) showed a continuous and significant 
TL decrease in relation to the control group (Figure 2).
An analysis of TDX in the first period showed that 
significant reductions started at 0.32 mmol/L bupivacaine 
(p<0.001) when compared to the control group. Significant 
reductions in TL had already occurred at concentrations of 
0.03 mmol/L (p=0.025) and 0.16 mmol/L (p<0.001) bupi-
vacaine, compared to the control.
Str was reduced significantly at 0.03 mmol/L (p=0.039) 
and again at 0.16 mmol/L and above (minimum p=0.033). 
V was significantly reduced and followed the trend for Str 
at 0.03 mmol/L (p=0.011), and at 0.16 mmol/L and above 
(minimum p=0.032).











IQR Relative Reduction to 
Control [%]
Control 278 225 – 0 278 225 –
0.03 226 309 81.3 * 0.007 385 259 138 *
0.09 236 252 84.9 * 0.14 357 221 128 *
0.16 239 308 86.0 * 0.71 328 243 118 *
0.32 102 206 36.7 * 1.42 329 273 118 *
0.63 77 197 27.7 * 3.55 0 0 0 *
0.95 50 75 18.0 * 7.1 0 0 0 *
1.58 0 0 0 * 14.21 0 0 0 *
3.16 0 0 0 *
Note: Asterisks (*) mark significant changes compared to the control group (see text for further details).
submit your manuscript | www.dovepress.com                                                                                                                                                                                                                    
DovePress                                                                                                                                                
Journal of Inflammation Research 2021:14 4



































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
TDY showed no significant difference between the 
bupivacaine groups and the control group, and scatter 
was around 0 µm, confirming with TDX > 0 µm an intact 
CA-gradient in x-direction and no perpendicular gradient.
Lidocaine
In the first 30 minutes, the median TL of cells exposed to 
0.007 mmol/L lidocaine showed a significantly (p=0.021) 
increased median track length of 385 µm (138% of control 
group; median TL 2nd period = 354 µm; 3rd period = 322 
µm) (Figure 3). Similarly, the TLs observed with 1.42 
mmol/L lidocaine significantly increased compared to the 
control group: the median TL during the first 30 minutes 
was 329 µm (118% of the median TL of the control 
group). However, in contrast to the lower doses of bupi-
vacaine, this effect changed in the second period 
(TL=207µm; 82.0% in relation to the control group; 
p=0.004) and in the third period (TL=75.5 µm; 45.3% of 
control group; p<0.001) without reaching significance. 
Migration was only detectable with up to 1.42 mmol/L 
of lidocaine. Higher concentrations resulted in immediate 
and absolute arrest at the beginning of the observation 
period. These results were considered significantly differ-
ent to every other group. (Figure 3)
Compared to the controls, every chosen concentration 
of lidocaine from 0.007 mmol/L to 14.21 mmol/L showed 
a significant effect on TL, but this effect was ambivalent. 
Lower doses (0.007 mmol/L–0.07 mmol/L) resulted in 
a higher TL, whereas doses above 1.42 mmol/L resulted 
in decreased migration and far earlier arrests.
TDY showed no significant difference between the 
lidocaine groups and the control group and scattered at 
around 0 µm due to perpendicular movement.
ROS Production
The entire time period was analyzed, and the median 
sample size without control (n=42) was n=3 for every 
condition. Within the control group, the median Tmax 
ROS was 115 minutes after cell-gel contact.
For bupivacaine, the detected ROS production showed 
no clear trend with increasing concentrations between 0.03 
and 0.63 mmol/L. The median TmaxROS for concentra-
tions between 0.03 and 0.63 mmol/L varied between 71 
and 164 minutes. In the cases of 0.95 mmol/L and 1.58 
mmol/L, TmaxROS could not be quantified because it 
Figure 2 Track Length [µm] during the first three 30-minute time periods clustered by increasing concentrations of bupivacaine. Higher concentrations resulted in complete 
migration arrest and are not shown in the figure. *Depicts extreme values and oIndicates outliers.
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reduced significantly in the time frame between PMN 
preparation and the start of microscopic observation.
For lidocaine, a decrease in TmaxROS values to 
between 100 and 110 minutes was detectable in concen-
trations of 0.007, 0.14, 0.71, 0.142, and 7.1 mmol/L. 14.21 
mmol/L lidocaine resulted in significantly reduced Tmax 
ROS during pre-observation.
Along with the above-mentioned absolute arrest of all 
cells, the detected ROS production showed no peak or had 
ended at the very beginning of microscopy. Therefore, no 
valid TmaxROS values could be recorded even though the 
interval between LA contact and microscopy was less than 
5 minutes (Table 3).
Oxidative Burst
The median number of oxidative burst measurements with 
local anesthetics was n=7 (range 6–12) for each condition. 
No significant changes between LA-exposure and the con-
trol group could be detected. Median fluorescence inten-
sities (MFI) obtained were at 533 for the control, 682 
(467–1419) for all concentrations of bupivacaine, and 
479 (521–565) for all concentrations of lidocaine after 
stimulation with PMA. fMLP and TNFa stimulation 
resulted in MFIs of 10 for the control group, 21 for all 
concentrations of bupivacaine (range 6–28) and 7 for all 
concentrations of lidocaine (range 5–9).
NETosis
For bupivacaine, the significant decrease started at 1.58 
mmol/L (Kruskal–Wallis: p=0.033) with a median ET50 
NET of 107 minutes, compared to the control group with 
a median ET50NET of 320 minutes. Looking at the highest 
tested concentration of 3.16 mmol/L (Kruskal–Wallis: 
p=0.074), a median ET50NET of 83 minutes was observed, 
equaling 26% of the mean ET50NET within the control group.
For lidocaine, significant and though dose-dependent 
paradoxical effects were observed. Concentrations of 0.-
007–1.42 mmol/L resulted in an increase in ET50NET, 
whereas concentrations of 7.1 mmol/L and above led to 
a decrease in ET50NET.
Maximal increase was seen with 0.71 mmol/L, 
resulting in an ET50NET of 429 minutes (Kruskal– 
Wallis: p=0.175). The decreases observed were more 
distinctive: with 7.1 mmol/L the ET50NET was 241 
minutes (Kruskal–Wallis: p=0.318), and with 14.21 
mmol/L – the highest concentration used - the ET50 
Figure 3 Track length [µm] during the first three 30-minute time periods clustered by increasing concentrations of lidocaine. Lidocaine concentrations above 1.42 mmol/L 
induced an immediate arrest of PMNs and are therefore not shown in the figure. oIndicates outliers.
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NET was reduced to 49 minutes (Kruskal–Wallis: 
p=0.227). A summary of all TmaxROS and ET50NET- 
values is shown in Table 3.
Based on the LA concentrations and their correspond-
ing ET50NET values, an inverse sigmoidal model was used 
to plot a curve for each LA to the data. The LA concen-
tration at 50% reduction of the initial effect level was 
defined as EC50. The calculated EC50 value of lidocaine 
equaled 7.96 mmol/L, while bupivacaine showed a higher 
potency with an EC50 concentration of 1.1 mmol/L 
(Figure 4).
Along with the above-mentioned absolute arrest of all 
cells, ROS production peaked before the beginning of 
microscopy. Therefore, no valid TmaxROS values were 
recorded even though the interval between LA contact 
and microscopy was less than 5 minutes.
Cell Viability
Cell viability was evaluated by flow cytometry. The percen-
tage of dead cells varied between 1.07% and 7.78% and 
exposure to LAs did not provoke any significant changes.
Cell-Surface Antigen Expression
The number of samples varied between 4 and 12 samples 
per condition (mean=6). The cell-surface antigen expres-
sion, measured by detecting the fluorescence intensity, 
showed no significant differences between the MFI of LA- 
exposed samples and the control group (Table 4).












Bupivacaine 0 115.5 ± 46.0 320.4 ± 47.5
0.03 101.6 ± 12.2 349.7 ± 31.4
0.09 81.47 ± 21.64 338.6 ± 35.6
0.16 88.5 ± 34.4 296.2 ± 34.0
0.32 164.4 ± 34.8 314.6 ± 12.4
0.63 70.5 ± 16.9 319.3 ± 39.0
0.95 229.8 ± 37.4
1.58 107.3 ± 29.3
3.2 83.0 ± 6.11
Lidocaine 0 115.5 ± 46.0
0.007 110.5 ± 24.8 355.8 ± 10.2
0.14 106.6 ± 6.1 356.3 ± 5.81
0.71 102.5 ± 21.5 428.9 ± 13.8
1.42 100.9 ± 17.2 392.0 ± 50.7
3.55 143.7 ± 38.0 343.9 ± 26.9
7.1 101.7 ± 35.7 240.7 ± 23.7
14.21 49.0 ± 18.8
Figure 4 Fitted curves of the LA dependent concentrations – ET50 connection indicating the induction of NETosis of human granulocytes by bupivacaine and lidocaine.
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An overview of the tendencies of all analyzed aspects 
is shown in Table 5.
Discussion
This study investigated the impact of clinically used doses of 
amide type local anesthetics bupivacaine and lidocaine on 
isolated PMNs with regard to granulocyte migration, time 
dependency of ROS production and NET formation, and 
viability.
The dosages of each of the LAs under investigation were 
chosen according to their use in the clinical setting. An 
incubation period of 30 minutes was chosen to prevent 
PMN activation due to contact with artificial surfaces at 
longer periods. Both drugs have been used in clinical routine 
for decades.9,10 As bupivacaine is not suitable for intravenous 
(iv) administration due to its adverse effects on both the 
cardiovascular and central nervous systems,9 the high con-
centrations in our study correspond to the tissue levels yielded 
locally after directly injecting 0.5% bupivacaine (correspond-
ing to approximately 15.8 mmol/L).9 Bupivacaine is adsorbed 
into the bloodstream from the injection site and distributed 
throughout the body, after which detectable plasma levels can 
be measured.9 Berrisford et al, for example, observed 
a plasma concentration of 1.45 µg/mL (equivalent to 0.005 
mmol/L) after administration of a 20 mL bolus of 0.5% 
bupivacaine for an intercostal nerve block. After a 48-hour 
continuous bupivacaine infusion of 2 mg/kg bodyweight 
(BW) via this intercostal block, the plasma concentration 
rose to 4.92 µg/mL (equivalent to 0.017 mmol/L).23
Lidocaine can be administered intravenously or 
locally.10,24 After a local injection of 2% lidocaine, tissue 
concentration is around 20.5 mg/mL (equivalent to 71.1 
mmol/L).10 For iv analgesia, Greenwood et al measured 
a plasma level of 4.6 µg/mL (equal to 0.016 mmol/L) after 
injecting an initial bolus of 1.5 mg/kg BW lidocaine followed 
by a continuous infusion of 120 mg/hour lidocaine for 
a bodyweight of 70 kg or more.25 In general, lidocaine plasma 
concentrations of up to 6 µg/mL (0.021 mmol/L) are consid-
ered safe during surgery and for anti-arrhythmic therapy.24,26
Granulocyte migration and migration efficacy 
decreased with increasing concentrations of bupivacaine. 
This result is in line with several other studies which have 
investigated the influence of local anesthetics on 
PMNs.4,5,27 Migration ceased at concentrations of 1.58 
mmol/L and above. Surprisingly in this study, lidocaine 
at lower concentrations of up to 1.42 mmol/L increased 
PMN migration. This result correlates with a study by 
Cook et al. They incubated equine neutrophils in vitro 
with therapeutic dosages of lidocaine, detecting increased 
migration with comparable concentrations of lidocaine.28 
Similar findings were observed by Erskine et al. In their 
study, granulocytes obtained from patients who had 
received spinal anesthesia for hip surgery showed greater 
Table 4 Results of Flow-Cytometric Detection on Cell-Surface 
















CD11b 569(3–1244) 560(126–1147) 620(386–1020)
CD62L 118(2–328) 142(62–328) 118(81–217)
CD66b 107(2–209) 106(10–337) 140(65–233)
Table 5 Summary of LA Effects on PMNs in Our in vitro Study
Local Anesthetic Bupivacaine Lidocaine








Clinical Location Intravascular Extravascular Intravascular Extravascular
Effect on PMNs
Viability ↔ ↔ ↔ ↔
CD66b (“Activation”) ↔ ↔ ↔ ↔
CD62L or CD11b (“Adhesion”) ↔ ↔ ↔ ↔
Chemotactic migration ↔ ↓↓↓ ↑ ↓↓↓
Induction period of ROS-production ↔ ↓↓↓ ↔ ↓↓↓
Intensity of ROS-production ↔ ↔ ↔ ↔
Duration until NETosis-Onset ↓ ↓↓↓ ↑ ↓↓↓
Note: ↔ indicates no change, ↑/↓ indicates slight increase or decrease and ↓↓↓ indicates strong decrease.
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movement than granulocytes from patients under general 
anesthesia.29 Furthermore, higher concentrations of lido-
caine led to reduced migration, matching several other 
studies.4–6,16 Migration stopped at concentrations beyond 
1.42 mmol/L. This occurrence may be due to an over-
whelming inactivation of the NaV 1.3 channel and the 
non-canonical effects exerted by local anesthetics,4,5,7,16 
or due to an increase in intracellular calcium concentra-
tion, as has been observed in investigations into the effect 
of LAs on tumor cell lines and muscle cells,30–32 though 
these investigations require further elucidation. Another 
study by Baptista-Hon et al revealed reduced rates of 
colon carcinoma cell invasion.33 Other studies investigat-
ing the effect of lidocaine administration during breast 
cancer surgery found reduced metastasis rates in patients 
treated with lidocaine.34,35
In a concentration-dependent manner, both LAs shifted 
ROS production towards an earlier onset. No ROS produc-
tion was observed at high concentrations of both LAs, as 
cells were activated at the beginning of the experiments 
and these cells stopped their metabolism before micro-
scopic observation began. These results are in line with 
several other studies.27,36,37 This observation is also likely 
to be attributed to the canonical and non-canonical effects 
of LAs as mentioned above.
Oxidative burst was unaffected for both substances 
investigated here. This result is in line with studies by 
Ploppa et al and by Mikawa et al, who did not observe 
a relevant change in oxidative burst for clinically used 
doses of local anesthetics.38,39 Contrary results were 
found by Billert et al36. In their study using PMNs 
obtained from cord blood of term newborns, a reduced 
oxidative burst at low concentrations of bupivacaine was 
observed, whereas, surprisingly, high concentrations did 
not result in decreased oxidative burst levels. However, 
high concentrations of lidocaine caused decreased oxida-
tive burst levels in their study.
NETosis, depicted by ET50NET in this study, was 
reduced in a concentration-dependent manner for both 
substances, with a low concentration of lidocaine resulting 
in a slight increase of NET formation as well as in migra-
tion. Bupivacaine resulted in a significantly earlier onset of 
NET formation when compared to lidocaine. This attrib-
uted to its greater lipophilic structure.
Other aspects of LA-induced granulocyte arrest and 
altered defense mechanisms lie beyond direct antimicro-
bial or anti-tissue effects. Recently, investigations into the 
interactions between NETs and cancer growth/metastasis 
have revealed a distressing prospect. Circulating tumor 
cells are “invited” by NETs to settle and proliferate via 
CCDC25, a NET-DNA-receptor found on tumor cells.40,41 
Bearing in mind that approximately 50% of all intravas-
cular granulocytes are located in the so-called “marginated 
pools”42 – meaning they are temporarily immobilized, 
mainly in the venules of the lungs, liver and kidneys – 
an LA-induced NET-DNA presenting a landing strip for 
released cancer cells may intensify metastases in these 
organs. Galos et al reported on reduced NETosis levels 
after i.v. administration of lidocaine during breast cancer 
surgery, which might lead to reduces recurrence rates.14 
Similar results were observed by Tohme et al for oncolo-
gic liver surgery.13
Cell viability was unaffected in our study. Other stu-
dies have shown a reduced survival of leucocytes when 
exposed to comparable concentrations of local anesthetics, 
but incubation was 24 hours, according to their 
protocols.43,44 Different cell types may have different sen-
sitivities to local anesthetic mediated toxicity. Breu et al, 
for example, observed significant damage to chondrocytes 
after a one-hour incubation period.45
Cell-surface antigen expression was unaffected by both 
substances investigated here. This is contrary to other 
studies showing reduced levels of CD11b, CD62L 
(Selectin) and CD66b with increasing concentrations of 
LAs.5,46–49 It is speculated that these findings are due to 
different cell separation methods and handling regimens.
Limitations
As we performed an in vitro study with a collagen- 
I-matrix we can simulate extravascular PMN migration 
after extravasation. Nevertheless, this in vivo situation 
might be different due to interferences. It also could be 
argued that we did not perform assays on phagocytosis, 
but ROS production is quantified by standard flow cyto-
metry and by time resolved fluorescence analysis. ROS 
production is the indispensable requirement for an effec-
tive killing of bacterial intruders and we already could 
show that the contact time between bacteria and the pha-
gosome is also of extraordinary importance. If the migra-
tion period is shortened by NETosis induction and 
NETosis occurs too early, already phagocyted, but still 
living bacteria are released gain. The antibacterial function 
(eg, trapping and MPO-effects) of NETs is undermined by 
an incomplete destruction of already ingested monads. 
A LA-induced premature NETosis is to be assumed to 
hinder antibacterial effectivity of PMNs (unpublished 
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data from our laboratory). Furthermore, we used incuba-
tion periods of 30 minutes. Other studies used different 
incubation times. To have a short time until start of PMN 
observation we purified the PMNs prior to incubation and 
did not incubate whole blood with the LAs. We have 
chosen this setup with a short time in contact with artificial 
surfaces and hypotonic lyses to prevent PMN activation 
due to other reasons then the LAs before microscopy. 
Furthermore, in our experimental setup life-cell-imaging 
requires observation periods of 8 hours. With longer incu-
bation periods of up to 3 or 4 hours, PMNs would have 
been out of the body for >12 hours probably generating 
activation and cell death during the subsequent observa-
tion period.
Conclusion
In conclusion, our experimental setup with in vitro exam-
inations of a collagen-I-matrix proves that PMN activity 
sequence starts with migration before the cells undergo 
conformational change, start ROS production, and finally 
undergo NETosis.50 Our data provide evidence that LAs in 
higher clinically applied concentrations have an inhibitory 
effect on PMN´s ability to migrate, the extent of this 
migration, and the ability to migrate efficiently. The time 
required until onset of ROS production and NETosis was 
reduced in a dose-dependent manner for both drugs, 
whereas the intensity and overall amount of ROS produc-
tion and NETosis were unaffected. Bupivacaine generated 
a greater impact at lower concentrations compared to 
lidocaine. Taken together, we hypothesize that 
a perioperative application of LAs is able to modulate 
surgical trauma (Table 5).
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